European Journal of Contraception and Reproductive Health Care最新文献

{"title":"Perception of oral contraception - do women think differently from gynaecologists?","authors":"Fátima Palma,&nbsp;Ana Rosa Costa,&nbsp;Joaquim Neves,&nbsp;Amália Pacheco,&nbsp;M Céu Almeida,&nbsp;Teresa Bombas,&nbsp;Daniel P Silva","doi":"10.1080/13625187.2023.2185482","DOIUrl":"https://doi.org/10.1080/13625187.2023.2185482","url":null,"abstract":"<p><strong>Purpose: </strong>This study aimed to assess the experience and satisfaction with contraceptives and use of Combined Oral Contraceptives (COC) by women and compare their perceptions with those of gynaecologists.</p><p><strong>Methods: </strong>This was a multicentre survey study conducted in Portugal, during April and May, 2021 with women using contraceptives and gynaecologists. Online quantitative questionnaires were carried out.</p><p><strong>Results: </strong>A total of 1508 women and 100 gynaecologists were included. Cycle control was the pill non-contraceptive benefit most valued by gynaecologists and women. For gynaecologists, the main pill concern was the risk of thromboembolic events, but they believed that weight gain was the main concern for their patients. The pill was the most used contraceptive (70%) and women were largely (92%) satisfied. The pill was associated with health risks for 85% of users, mainly thrombosis (83%), weight gain (47%), and cancer (37%). The attributes of the pill most valued by women are contraceptive efficacy (82%), followed by low risk of thromboembolic events (68%), good cycle control (60%), non-interference with libido and mood (59%) and weight (53%).</p><p><strong>Conclusion: </strong>Most women use contraceptive pills and are generally satisfied with their contraceptive. Cycle control was the most valued non-contraceptive benefit for gynaecologists and women, agreeing with physicians' beliefs about women. On the other hand, contrary to physicians' beliefs, that women's main concern is weight gain, women are mainly concerned with risks associated with contraceptives. Thromboembolic events are women's and gynaecologists most valued risk. Finally, this study indicates the need for physicians to better understand what COC users really fear.</p>","PeriodicalId":50491,"journal":{"name":"European Journal of Contraception and Reproductive Health Care","volume":null,"pages":null},"PeriodicalIF":1.7,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9288395","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Interventions to support contraceptive choice and use: a global systematic map of systematic reviews.","authors":"Preethy D'Souza,&nbsp;Tenzin Phagdol,&nbsp;Sonia R B D'Souza,&nbsp;D S Anupama,&nbsp;Baby S Nayak,&nbsp;Binil Velayudhan,&nbsp;Julia V Bailey,&nbsp;Judith Stephenson,&nbsp;Sandy Oliver","doi":"10.1080/13625187.2022.2162337","DOIUrl":"https://doi.org/10.1080/13625187.2022.2162337","url":null,"abstract":"<p><strong>Background: </strong>To review the highest level of available evidence, a systematic map identified systematic reviews that evaluated the effectiveness of interventions to improve contraception choice and increase contraception use.</p><p><strong>Methods: </strong>Systematic reviews published since 2000 were identified from searches of nine databases. Data were extracted using a coding tool developed for this systematic map. Methodological quality of included reviews was assessed using AMSTAR 2 criteria.</p><p><strong>Findings and conclusion: </strong>Fifty systematic reviews reported evaluations of interventions for contraception choice and use addressing three domains (individual, couples, community); Meta-analyses in 11 of the reviews mostly addressed interventions for individuals. We identified 26 reviews covering High Income Countries, 12 reviews covering Low Middle-Income Countries and the rest a mix of both. Most reviews (15) focussed on psychosocial interventions, followed by incentives (6) and m-health interventions (6). The strongest evidence from meta-analyses is for the effectiveness of motivational interviewing, contraceptive counselling, psychosocial interventions, school-based education, and interventions promoting contraceptive access, demand-generation interventions (community and facility based, financial mechanisms and mass media), and mobile phone message interventions. Even in resource constrained settings, community-based interventions can increase contraceptive use. There are gaps in the evidence on interventions for contraception choice and use, and limitations in study designs and lack of representativeness. Most approaches focus on individual women rather than couples or wider socio-cultural influences on contraception and fertility. This review identifies interventions which work to increase contraception choice and use, and these could be implemented in school, healthcare or community settings.</p>","PeriodicalId":50491,"journal":{"name":"European Journal of Contraception and Reproductive Health Care","volume":null,"pages":null},"PeriodicalIF":1.7,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9642597","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Acceptance rate of post-placental plac ement of intrauterine devices during the SARS-CoV-2 (COVID-19) pandemic.","authors":"Rodolfo R Jacapenga,&nbsp;Fernanda Surita,&nbsp;Luis Bahamondes,&nbsp;Cássia R T Juliato","doi":"10.1080/13625187.2023.2173004","DOIUrl":"https://doi.org/10.1080/13625187.2023.2173004","url":null,"abstract":"<p><strong>Objective: </strong>To evaluate the acceptance rate of post-placental intrauterine device (PPIUD) placement during the SARS-CoV-2 (COVID-19) pandemic and to to assess factors associated with PPIUD acceptance.</p><p><strong>Methods: </strong>A cross-sectional study was conducted between August 2020 and August 2021. PPIUDs were offered to women scheduled for caesarean delivery or admitted in labour at the Women's Hospital of the University of Campinas. The study compared women according to whether they accepted or did not accept the IUD placement. The factors associated with PPIUD acceptance were analysed through bivariate and multiple logistic regression analyses.</p><p><strong>Results: </strong>We enrolled 299 women (15.9% of the deliveries that occurred during study period), aged 26.8 ± 6.5 years; 41.8% were White, almost one third were primiparous, and 155/299 (51.8%) had a vaginal delivery. The PPIUD acceptance rate was 65.6%. The principal reason for refusal was the desire for another contraceptive (41.8%). Women with the highest likelihood of accepting a PPIUD were younger (<30 years old has 1.7 more likely or 74% greater), those without a partner (3.4 times more likely) and those after vaginal delivery (1.7 times more likely or 69% greater).</p><p><strong>Conclusion: </strong>The COVID-19 does not affected the PPIUD placement. PPIUD is a viable alternative during crisis in which women has difficult to access health services. Younger women, those without a partner and after vaginal delivery were more likely to accept a PPIUD during the COVID-19 pandemic.</p>","PeriodicalId":50491,"journal":{"name":"European Journal of Contraception and Reproductive Health Care","volume":null,"pages":null},"PeriodicalIF":1.7,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9341303","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"How often is oral contraception used for contraception? The need of benefit's formalisation.","authors":"Angelo Cagnacci,&nbsp;Vincenzina Bruni,&nbsp;Costantino Di Carlo,&nbsp;Franca Fruzzetti","doi":"10.1080/13625187.2023.2170711","DOIUrl":"https://doi.org/10.1080/13625187.2023.2170711","url":null,"abstract":"Since its introduction in the early 1960s, the oral contraceptive pill has been taken by millions of women. The pill has allowed women to independently determine their reproductive life, relieving them from the burden of unwanted pregnancies. The social impact has been enormous, with women now achieving higher education levels and being able to fulfil their career and social ambitions. Even though other contraceptives methods have since been developed, some with superior efficacy [1], the pill remains one of the most used contraceptive methods throughout the world and the most used in Europe [2,3]. Every time our mind turns to contraception, the first method we think of is the pill. However, there may be other reasons why it is so commonly prescribed today. As physicians, we all know that the hormones contained in the pill can help treat many ailments afflicting women. These non-contraceptive benefits are outlined in scientific papers [4,5], but are not mentioned in leaflets provided with the pill, nor are they sufficiently considered in scientific debates focussed on the risks associated with the use of oral contraception. Still noncontraceptive benefits are displayed on public websites (for example https://www.webmd. com/sex/birth-control/other-benefits-birth-control or https:// www.Healthline.com/health/birth-control-benefits), and likely considered by the woman who choose a contraceptive method [6–8]. How much non-contraceptive benefits account for pill prescription rates is unclear, particularly in Europe. However, some insight on this issue is given by a recent post-marketing study, designed to evaluate the efficacy and cardiovascular safety of micronized oestradiol 1.5mg and nomegestrol acetate 2.5mg vs. other oral contraceptive pills [9,10]. The study was performed between 2010 and 2021, on 91,313 women, recruited in Russia (n1⁄4 36,092; 39.5%) Italy (n1⁄4 19,683; 21.6%), Hungary (n1⁄4 9,407; 10.3%), Spain (n1⁄4 8,656; 9.5%), Poland (n1⁄4 6,263; 6.9%), Germany (n1⁄4 4,712; 5.2%), France (n1⁄4 580; 0.6%), Sweden (n1⁄4 517; 0.6%) and Austria (n1⁄4 462; 0.5%). At enrolment, physicians recorded the reason why they were prescribing the oral contraceptive pill, either: 1. for contraception only; 2. for contraception and therapeutic reasons; 3. for therapeutic reasons only. The Italian company marketing the pill under investigation (Theramex Italy SRL, Milan, Italy) provided datasets for the entire study and for the Italian cohort, separately (data on file). Overall, the pill was prescribed for contraception alone in 56.5% of cases, and for therapeutic reasons in 42.5%, either with (33.5%) or without additional contraceptive purposes (9.1%). In Italy, the pill was prescribed for contraception alone in 38.8% of cases, and for therapeutic reasons in 61% of cases, either with (44.2%) or without additional contraceptive purposes (16.7%). The reasons for non-contraceptive prescription was stated as: treatment of cycle irregularity (44.3%), menstrual ","PeriodicalId":50491,"journal":{"name":"European Journal of Contraception and Reproductive Health Care","volume":null,"pages":null},"PeriodicalIF":1.7,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9329542","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Editors' response.","authors":"Giovanni Grandi,&nbsp;Frans Roumen,&nbsp;Johannes Bitzer","doi":"10.1080/13625187.2023.2183648","DOIUrl":"https://doi.org/10.1080/13625187.2023.2183648","url":null,"abstract":"","PeriodicalId":50491,"journal":{"name":"European Journal of Contraception and Reproductive Health Care","volume":null,"pages":null},"PeriodicalIF":1.7,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9293339","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"User satisfaction with an intrauterine system containing 52 mg levonorgestrel: a Portuguese study.","authors":"Cristina Nogueira-Silva,&nbsp;Ana Rolhas,&nbsp;Irina Ramilo,&nbsp;Marta Plancha,&nbsp;Daniel Pereira da Silva","doi":"10.1080/13625187.2023.2174375","DOIUrl":"https://doi.org/10.1080/13625187.2023.2174375","url":null,"abstract":"<p><strong>Objective: </strong>To characterise patient satisfaction 6 and 12 months after insertion of a 52 mg levonorgestrel-releasing intrauterine system (LNG-IUS) in Portuguese women.</p><p><strong>Study design: </strong>A non-interventional and prospective study was conducted in Portuguese women of reproductive age who had Levosert^® inserted. Two questionnaires (administered 6 and 12 months after 52 mg LNG-IUS insertion) were used to collect information on the patients' menstrual pattern, discontinuation rate, and satisfaction rate with Levosert^®.</p><p><strong>Results: </strong>A total of 102 women were enrolled, of which only 94 (92.2%) completed the study. Seven participants discontinued the use of the 52 mg LNG-IUS. At 6 and 12 months, 90.7% and 90.4% of participants, respectively, were either satisfied or very satisfied with the 52 mg LNG-IUS. At 6 and 12 months, 73.2% and 72.3% of participants, respectively, indicated that they were very likely to recommend the 52 mg LNG-IUS to a friend or family member. Most women (92.2%) continued to use the 52 mg LNG-IUS for the first year. The percentage of women who were 'much more satisfied' with Levosert^® than with their previous contraceptive methods was 55.9% and 57.8% at 6 and 12 months, respectively, per questionnaire assessment. Satisfaction was associated with age (<i>p</i> = 0.004), amenorrhoea (<i>p</i> < 0.003) and absence of dysmenorrhoea (<i>p</i> = 0.003), but not with parity (<i>p</i> = 0.922).</p><p><strong>Conclusions: </strong>These data suggest that the continuation and satisfaction rates with Levosert^® were very high, and that this system is well accepted among Portuguese women. Patient satisfaction was driven by a favourable bleeding pattern and absence of dysmenorrhoea.</p>","PeriodicalId":50491,"journal":{"name":"European Journal of Contraception and Reproductive Health Care","volume":null,"pages":null},"PeriodicalIF":1.7,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9642596","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Usage of postpartum intrauterine contraceptive device (postpartum-IUD) after an increase in the institutional delivery rate in India: time to re-visit the effect of timing of counselling on its acceptance.","authors":"Nancy Bhagat,&nbsp;Rimpi Singla,&nbsp;Minakshi Rohilla,&nbsp;Aashima Arora,&nbsp;Vanita Suri","doi":"10.1080/13625187.2023.2187249","DOIUrl":"https://doi.org/10.1080/13625187.2023.2187249","url":null,"abstract":"<p><strong>Purpose: </strong>While increase in institutional deliveries brings an opportunity to counsel women for postpartum family planning (PPFP), its uptake remains low. Reasons for poor acceptance of postpartum intrauterine contraceptive device (postpartum-IUD), and its relation with the timing of counselling need to be investigated.</p><p><strong>Methods: </strong>Women attending the antenatal clinic, reporting in labour, and within 48 h of delivery respectively were invited to participate. Eligible women were asked about awareness and choice for PPFP. After counselling, acceptance for PPFP was compared with the baseline. Acceptance and continuation of postpartum-IUD were compared between women counselled in the antenatal, intrapartum, and postpartum periods.</p><p><strong>Results: </strong>Only 23% of 360 women were aware of postpartum-IUD. After counselling, acceptance for PPFP increased from 14% to 97% and for postpartum-IUD, from 0.5% to 33.9%. Acceptance of postpartum-IUD among women counselled in the antenatal, intrapartum and postpartum period was 45%, 35% and 21.7% respectively. Acceptance was higher among the antenatal-counselling group than the postpartum-counselling group (OR 0.45; CI 0.22-0.94; <i>p</i> = 0.03).</p><p><strong>Conclusion: </strong>Counselling, irrespective of its timing, improves acceptance for PPFP. Acceptance and continuation of postpartum-IUD are higher following counselling in antenatal period. All eligible women should be counselled irrespective of 'when' they approach the facility.</p>","PeriodicalId":50491,"journal":{"name":"European Journal of Contraception and Reproductive Health Care","volume":null,"pages":null},"PeriodicalIF":1.7,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9288396","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"What is the optimal tool for measuring abortion stigma? A systematic review.","authors":"Sarah E Ratcliffe,&nbsp;Clare S Smylie,&nbsp;Rebecca T Pinkus,&nbsp;Ilan Dar-Nimrod,&nbsp;Ilona Juraskova,&nbsp;Haryana M Dhillon","doi":"10.1080/13625187.2023.2177506","DOIUrl":"https://doi.org/10.1080/13625187.2023.2177506","url":null,"abstract":"<p><strong>Purpose: </strong>Abortion stigma is a barrier to accessing and delivering comprehensive, sustainable healthcare. This study aimed to systematically identify measures of abortion stigma, and assess their psychometric properties and uses.</p><p><strong>Materials and methods: </strong>The systematic review was preregistered with PROSPERO (ID#127339) and adhered to Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Eight databases were screened for articles measuring abortion stigma. Data were extracted by four researchers and checked for accuracy by two reviewers. Psychometric properties were assessed with COSMIN guidelines.</p><p><strong>Results: </strong>Of 102 articles reviewed, 21 reported original measures of abortion stigma. Instruments assessed individual and community level stigma for people who have had an abortion (<i>n</i> = 8), healthcare professionals (<i>n</i> = 4), and the public (<i>n</i> = 9), and predominantly originated from the United States (U.S.). Measures varied in structure, use, and comprehensiveness of psychometric properties. On psychometric properties, the Individual Level Abortion Stigma scale and Abortion Provider Stigma Scale - Revised performed best for individual-level stigma and the Stigmatising Attitudes, Beliefs and Actions Scale for community-level stigma.</p><p><strong>Conclusion: </strong>Gaps in abortion stigma measurement include geography, conceptualisation, and structural-level stigma. Continued development and testing of tools and methods for measuring abortion stigma is needed.</p>","PeriodicalId":50491,"journal":{"name":"European Journal of Contraception and Reproductive Health Care","volume":null,"pages":null},"PeriodicalIF":1.7,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9642600","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Telemedicine medical abortion service in Georgia: an evaluation of a strategy with reduced number of in-Clinic visits.","authors":"Nino Tsereteli,&nbsp;Lia Mamatsashvili,&nbsp;George Tsertsvadze,&nbsp;Tamar Tsereteli,&nbsp;Ingrida Platais","doi":"10.1080/13625187.2023.2170710","DOIUrl":"https://doi.org/10.1080/13625187.2023.2170710","url":null,"abstract":"<p><strong>Purpose: </strong>To evaluate feasibility and acceptability of a medical abortion service that offers: a telemedicine visit (in place of an in-person visit) during a mandatory waiting period, and at-home follow-up with the use of multi-level pregnancy tests (MLPT).</p><p><strong>Methods: </strong>Participants were screened for eligibility in clinic, and during the waiting period, received a telephone call to confirm desire to proceed with the service. Participants were mailed a study package containing mifepristone, misoprostol, two multi-level pregnancy tests, and instructions for their use. Follow-up consultation took place by phone to evaluate abortion completeness. The analysis was descriptive.</p><p><strong>Results: </strong>One-hundred twenty-two participants were enrolled in the study, and 120 chose to proceed with the abortion after the waiting period and were sent a study package. One participant was lost to follow up. The majority of participants did not experience problems receiving the study package (94.1%, <i>n</i> = 112), took mifepristone (100%, <i>n</i> = 119), misoprostol (99.2%, <i>n</i> = 118), and MLPTs (99.1%, <i>n</i> = 116) as instructed, and forwent additional clinic visits (91.6%, <i>n</i> = 109). All participants were satisfied with the service. Most participants had a complete abortion without a procedure (95.8%, <i>n</i> = 114).</p><p><strong>Conclusions: </strong>The adapted telemedicine medical abortion service was feasible and satisfactory to participants and has the potential to make medical abortion more patient-centered where waiting periods are mandated.</p>","PeriodicalId":50491,"journal":{"name":"European Journal of Contraception and Reproductive Health Care","volume":null,"pages":null},"PeriodicalIF":1.7,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9341270","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction.","authors":"","doi":"10.1080/13625187.2023.2187161","DOIUrl":"https://doi.org/10.1080/13625187.2023.2187161","url":null,"abstract":"","PeriodicalId":50491,"journal":{"name":"European Journal of Contraception and Reproductive Health Care","volume":null,"pages":null},"PeriodicalIF":1.7,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9650087","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}